HES1 and breast carcinoma: For example, in colon and breast cancers, Hes1 overexpression downregulates epithelial markers (e.g., E-cadherin) and upregulates mesenchymal markers (N-cadherin, vimentin), thereby inducing EMT and accelerating tumor proliferation, invasion, metastasis, and drug resistance (81–83).